Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal Reuters
ZURICH (Reuters) – Swiss company Roche will buy US biopharma company Poseida Therapeutics for up to $1.5 billion, the companies said on Tuesday.
Poseida will be purchased for $9 per share, and shareholders will receive the right to a potential sale price of up to $4 per share if certain milestones are met, valuing the deal at approximately $1.5 billion.
It is expected to close in the first quarter of 2025.
“We have worked closely with Roche through our collaboration focused on hematological interventions, and we are excited to join Roche to work as partners together throughout our pipeline and future plans,” said Kristin Yarema, president and CEO of San Diego-based Poseida, in a statement.
Poseida and its employees will join Roche as part of the Swiss pharmaceutical division, Poseida said.
The acquisition will establish a new capability for Roche in the treatment of allogeneic cells, with opportunities focused on CAR-T programs covered by the existing collaboration between Poseida and Roche in hematological disorders, the US company said.
It will include CAR-T programs for solid tumors and autoimmune diseases, as well as Poseida’s genetic engineering platform and related preclinical drugs, it added.
